Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.71 |
| ▸ | THRB | P10828 | 4/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1718569 | 0.92 | MAPT (0.72) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1720013 | 0.92 | MAPT (0.76) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1719103 | 0.90 | TP53 (0.70) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1718822 | 0.86 | MAPT (0.66) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1718901 | 0.86 | MAPT (0.75) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL823135 | 0.85 | MAPT (0.78) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL822398 | 0.85 | MAPT (0.61) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1718910 | 0.85 | THRB (0.79) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1719697 | 0.84 | THRB (0.77) | MAPTTHRBRXFP1SMN1; SMN2KDM4E | |
| SCHEMBL1718145 | 0.83 | MAPT (0.77) | MAPTTHRBRXFP1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198891-B2 | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase | NEW YORK UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | NEW YORK UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | ERN1, ERN2, EEF2K | MAPT 2510/4885THRB 1381/4885RXFP1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.